Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ischemic Heart Disease: early-phase trial registry
6 of 15 indexed Ischemic Heart Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 6 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Ischemic Heart Disease: 15 US clinical trials tracked, 6 recruiting.
Ischemic Heart Disease is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is NYU Langone Health, running 3 of these trials.
Enrollment posture brief
Registry condition ischemic-heart-disease
OPEN 6 | RECR 40% | LATE 1 | EARLY 3 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Ischemic Heart Disease lists 6 open slots (40% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ischemic Heart Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ischemic Heart Disease is recruiting below its size-band peers.
6 of 15 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ischemic Heart Disease research.
NYU Langone Health accounts for 3 of 15 trials (20%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Ischemic Heart Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 15 trials that report a genuine target (sentinel values excluded). 7 of those (46.7%) plan for fewer than 100 participants.
-
Ischemic Heart Disease splits between interventional and observational designs.
8 interventional and 7 observational studies make up this index (53.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Peerbridge Health
NCT06699056
Development of CIRC Technologies
The Cleveland Clinic
NCT05654272
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
NYU Langone Health
NCT05788666
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
Bettina Mittendorfer
NCT07083557
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
Roberto Bolli
NCT06145035
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
Pasquale Santangeli
NCT06891456
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
NYU Langone Health
NCT03537586
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests
NYU Langone Health
NCT00907855
Chronic Total Occlusion Percutaneous Coronary Intervention Study
Vascular Solutions
NCT03988166
Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
National Heart, Lung, and Blood Institute (NHLBI)
NCT00354328
A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
Abbott Medical Devices
NCT01186198
Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Washington University School of Medicine
NCT00881218
Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion
Yale University
NCT01137409
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
Gilead Sciences
NCT01847391
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
Washington University School of Medicine
NCT01779869
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ischemic Heart Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ischemic Heart Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ischemic Heart Disease page
15 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Ischemic Heart Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NYU Langone Health sponsors the most Ischemic Heart Disease trials on record, review their full trial history before evaluating a specific study. See NYU Langone Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ischemic Heart Disease condition card totals 15 registered trials; most-linked intervention Regadenoson; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.